Ariel Galindo-Albarrán

Ariel Galindo-Albarrán

Auto-generated profile, based on publicly available information

Ariel Galindo-Albarrán

UMR 8030 Génomique Métabolique, Genoscope, Institut François Jacob, CEA, CNRS, University of Evry-val-d’Essonne, University Paris-Saclay, Évry, France

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2017 in Nature Genetics
Verified
Journal Article
Closed access
LDLan T M Dao
Lan T M Dao
AGAriel O Galindo-Albarrán
Ariel O Galindo-Albarrán
JCJaime A Castro-Mondragon
Jaime A Castro-Mondragon
CACharlotte Andrieu-Soler
Charlotte Andrieu-Soler
AMAlejandra Medina-Rivera
Alejandra Medina-Rivera
SSSalvatore Spicuglia
Salvatore Spicuglia

1 November 2016 in Cell Reports
Verified
Journal Article
Open access
AGAriel O. Galindo-Albarrán
Ariel O. Galindo-Albarrán
OLOscar H. López-Portales
Oscar H. López-Portales
DGDarely Y. Gutiérrez-Reyna
Darely Y. Gutiérrez-Reyna
OROtoniel Rodríguez-Jorge
Otoniel Rodríguez-Jorge
JSJosé Antonio Sánchez-Villanueva
José Antonio Sánchez-Villanueva
MSM. Angélica Santana
M. Angélica Santana
To better understand why human neonates show a poor response to intracellular pathogens, we compared gene expression and histone modification profiles of neonatal naive CD8+ T cells with that of their adult counterparts. We found that neonatal lymphocytes have a distinct epigenomic landscape associated with a lower expression of genes involved in T cell receptor (TCR) signaling and cytotoxicity and a higher expression of genes involved in the cell cycle and innate immunity. Functional studies corroborated that neonatal CD8+ T cells are less cytotoxic, transcribe antimicrobial peptides, and produce reactive oxygen species. Altogether, our results show that neonatal CD8+ T cells have a specific genetic program biased toward the innate immune response. These findings will contribute to better diagnosis and management of the neonatal immune response.

30 July 2020 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
JDJulie Darrigues
Julie Darrigues
JSJeremy C. Santamaria
Jeremy C. Santamaria
AGAriel Galindo‐Albarrán
Ariel Galindo‐Albarrán
EREllen A. Robey
Ellen A. Robey
OJOlivier P. Joffre
Olivier P. Joffre
PRPaola Romagnoli
Paola Romagnoli

27 August 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
AKAlexander Kowar
Alexander Kowar
JBJonas P. Becker
Jonas P. Becker
RPRossella Del Pizzo
Rossella Del Pizzo
ZTZhiwei Tang
Zhiwei Tang
JCJulien Champagne
Julien Champagne
FLFabricio Loayza-Puch
Fabricio Loayza-Puch
Mitosis is a critical phase of the cell cycle and a vulnerable point where cancer cells can be disrupted, causing cell death and inhibiting tumor growth. Challenges such as drug resistance persist in clinical applications. During mitosis, mRNA translation is generally downregulated, while non-canonical translation of specific transcripts continues. Here, we show that mitotic cancer cells redistribute ribosomes toward the 5′ untranslated region (5′ UTR) and beginning of the coding sequence (CDS), enhancing translation of thousands of upstream open reading frames (uORFs) and upstream overlapping open reading frames (uoORFs). This mitotic induction of uORF/uoORF enriches human leukocyte antigen (HLA) presentation of non-canonical peptides on the surface of cancer cells after mitotic inhibitor treatment. Functional assays indicate these epitopes provoke cancer-cell killing by T cells. Our findings highlight the therapeutic potential of targeting uORF/uoORF-derived epitopes with mitotic inhibitors to enhance immune recognition and tumor cell elimination.

9 July 2013 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
AGA.O. Galindo‐Albarrán
A.O. Galindo‐Albarrán
ORO. Ramírez‐Pliego
O. Ramírez‐Pliego
RLR.G. Labastida‐Conde
R.G. Labastida‐Conde
EME.I. Melchy‐Pérez
E.I. Melchy‐Pérez
ALA. Liquitaya‐Montiel
A. Liquitaya‐Montiel
MSM.A. Santana
M.A. Santana

2 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
PBPaula Barbao
Paula Barbao
ARAlba Rodríguez-García
Alba Rodríguez-García
AGAriel Galindo-Albarrán
Ariel Galindo-Albarrán
MGMarta Giménez-Alejandre
Marta Giménez-Alejandre
PCPablo Clavero
Pablo Clavero
SGSonia Guedan
Sonia Guedan
CAR-T cell therapy has shown limited efficacy in solid tumors, largely due to T cell dysfunction driven by chronic antigen exposure. To uncover mediators of this dysfunction, we developed an in vivo screening platform using an ovarian xenograft tumor model in which CD28-based CAR-T cells undergo exhaustion leading to tumor escape. Transcriptomic profiling of tumor-infiltrating CAR-T cells at different stages revealed dynamic upregulation of exhaustion-associated genes. We used this data to design a focused CRISPR/Cas9 library and performed an in vivo screen. We identified 14 significantly enriched candidate genes, among which ZC3H12C emerged as the top hit. Single-cell RNA and ATAC-seq confirmed ZC3H12C expression in CAR-T cells undergoing early exhaustion in vivo . ZC3H12C disruption enhanced CAR-T cell persistence and antitumor efficacy while reducing exhaustion, across both CD28- and 4-1BB-based CARs targeting distinct antigens. These results highlight ZC3H12C as a promising target to improve CAR-T therapy in solid tumors.